Positioning Inebilizumab: A Distinct Approach in the Evolving gMG Treatment Landscape

The treatment landscape for generalized myasthenia gravis has expanded significantly in recent years, with multiple biologic therapies targeting different points along the disease pathway. As clinicians navigate these options, understanding how mechanisms of action translate into clinical outcomes is essential for selecting the most appropriate therapy for individual patients.

At the 2026 AAN Annual Meeting in Chicago, Richard Nowak, MD, MS, associate professor of neurology at Yale School of Medicine, spoke with NeurologyLive® about how inebilizumab compares with other available biologics, including complement inhibitors and FcRn antagonists. With its CD19-directed mechanism, the therapy introduces a distinct approach that focuses on upstream drivers of disease rather than downstream immune pathways.

In this episode, Nowak explains how inebilizumab may be positioned as a longer-term, disease-modifying strategy, emphasizing its infrequent dosing, sustained response, and lack of symptom fluctuation over time. He also discusses how this approach may complement existing therapies while offering a unique mechanism within the broader gMG treatment paradigm.